Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Sponsor and Collaborators
Celgene Corporation
Multiple Myeloma Research Consortium
Contact
Bond V. Vo, PharmD, RPh
+ 1 (908) 673-9232
[email protected]
Investigator
Ye Hua, MD, MPH
Celgene Corporation
ClinicalTrials.gov Identifier
NCT01497093
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.